Article
Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Antiviral therapy - 1 Jan 2005
Wainberg Mark A, Sawyer James P C, Montaner Julio S G, Murphy Robert L, Kuritzkes Daniel R, Raffi Francois
Abstract excerpt
There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these agents (for example, their cross-resistance, resistance threshold and interaction profiles), the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
